drugset / Trial / NCT01266655

Baclofen for the Treatment of Alcohol Dependence

NCT01266655

Phase 2/3 Completed 56 enrolled Charite University, Berlin, Germany
RandomizedParallel-groupQuadruple-blindTreatment

Summary

There is first evidence from preclinical and clinical studies for the efficacy of the selective GABA-B receptor agonist baclofen in the treatment of alcohol dependence. The aim of this trial is to evaluate the efficacy and safety of individually titrated high-dose baclofen for relapse prevention in alcohol-dependent patients.

Timeline

Start
2011-02
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Baclofen Small molecule 90 mg Oral

Indications